

09/147919



REC'D	27 OCT 1997
WIPO	PCT

Kongeriget Danmark

PRIORITY DOCUMENT

Patent application No.: 1035/96

Date of filing: 24 Sep 1996

Applicant: Bavarian Nordic Research Institute A/S,- Na-
verland 2, 2600 Glostrup, DK

This is to certify the correctness of the following information:

The attached photocopy is a true copy of the following document:

- The specification, claims, abstract and drawings as filed with the application on the filing date indicated above.



Erhvervsministeriet
Patentdirektoratet

TAASTRUP 29 Aug 1997

Gurli Brehmer
Gurli Brehmer
Kontorfuldmægtig



1 0 3 5 / 9 6 2 4 SEP. 96

BN 12 DK

24 September 1996

TITEL: Recombinant MVA virus der udtrykker Dengue virus antigener, og vacciner baseret på sådanne recombinate MVA virus.

OPFINDER: Gerd Sutter

ANSØGER: Bavarian Nordic Research Institute

Recombinant MVA virus expressing Dengu Virus Antigens, and th us thereof in Vaccines

The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) encoding and capable of expressing dengue virus antigens, and the use of such recombinant MVA viruses encoding dengue virus antigens in vaccines.

Background of the Invention

Dengue virus, with its four serotypes Den-1 to Den-4, is the most important member of the Flavivirus genus with respect to infections of humans producing diseases that range from flu-like symptoms to severe or fatal illness, dengue hemorrhagic fever with shock syndrome. Dengue outbreaks continue to be a major public health problem in densely populated areas of the tropical and subtropical regions, where mosquito vectors are abundant. Therefore, there is a substantial need for the development of prophylactic vaccines. Previous efforts to prepare live candidate dengue vaccines were mainly based on classical attenuation of dengue virus by serial passage in animals or in cultured cells of nonnatural hosts. However, this approach has not been consistently successful in producing attenuated vaccine strains. Available data indicate that recovery and protective immunity after dengue virus infection are correlated to the development of high titers of virus neutralizing antibodies. However, this immunity is homotypic mediating resistance to the same virus serotype only. Moreover, individuals immune to one dengue virus serotype may be even at higher risk of developing severe dengue illness if reinfected with another serotype. To overcome these problems an ideal vaccine should therefore induce solid immunity against all four dengue virus serotypes.

Knowledge about the molecular biology of flaviviruses rapidly increased during the last decade, and led to the application of recombinant techniques for the production of new vaccine candidates. These approaches have included *E. coli* fusion proteins, baculo virus expressed recombinant proteins, and live recombinant vaccinia viruses. Notably, the vaccinia approaches have given promising results. In mice, total protection against lethal challenge with dengue virus has been achieved after

immunization with recombinant vaccinia viruses expressing structural and/or non-structural genes of dengue virus. However, occurrence of rare adverse reactions to smallpox vaccination and the increased susceptibility of immunodeficient individuals has made further attenuation and improved safety a priority for human vaccines based on recombinant vaccinia virus.

Previous results from vaccine trials in animal models indicated that immune responses to structural preM and E proteins, or non-structural NS1 proteins were fully protective against a lethal challenge with homotypic dengue virus (Zhao et al. 1987 *J. Virol.* 61:4019; Bray et al. 1989 *J. Virol.* 63:2853; Falgout et al. 1990 *J. Virol.* 64:4356; Fonseca et al. 1994 *Vaccine* 12:279; Srivastava et al. 1995 *Vaccine* 13:1251).

The modified vaccinia virus Ankara (MVA) has been generated by long-term serial passages of the Ankara strain of vaccinia virus (CVA) on chicken embryo fibroblasts (for review see Mayr, A., Hochstein-Mintzel, V. and Stickl, H. [1975] *Infection* 3, 6-14; Swiss Patent No. 568, 392). The MVA virus was deposited in compliance with the requirements of the Budapest Treaty at CNCM (Institut Pasteur, Collection Nationale de Cultures de Microorganismes, 25, rue du Docteur Roux, 75724 Paris Cedex 15) on Dec. 15, 1987 under Depositary No. I-721. The MVA virus has been analysed to determine alterations in the genome relative to the wild type CVA strain. Six major deletions of genomic DNA (deletion I, II, III, IV, V, and VI) totaling 31,000 base pairs have been identified (Meyer, H., Sutter, G. and Mayr A. [1991] *J. Gen. Virol.* 72, 1031-1038). MVA is distinguished by its great attenuation, that is to say by diminished virulence or infectiosity while maintaining good immunogenicity. When tested in a variety of animal models, MVA was proven to be avirulent even in immunosuppressed animals. More importantly, the excellent properties of the MVA strain have been demonstrated in extensive clinical trials (Mayr et al., *Zbl. Bakt. Hyg. I, Abt. Org. B* 167, 375-390 [1987], Stickl et al., *Dtsch. med. Wschr.* 99, 2386-2392 [1974]). During these studies in over 120,000 humans, including high risk patients, no side effects were associated with the use of MVA vaccine. MVA replication in human cells was found to be blocked late in infection preventing the assembly to mature infectious virions. Nevertheless, MVA was able to express viral and recombinant genes at high levels even in non-permissive cells and was proposed to serve as an efficient and exceptionally safe gene expression vector (Sutter, G. and Moss, B. [1992] *Proc. Natl. Acad. Sci. USA* 89, 10847-10851). Recently, novel vaccinia vector systems were established on the basis of MVA, having foreign

DNA sequences inserted at the site of deletion III within the MVA genome or within the TK gene (Sutter, G. and Moss, B. [1995] Dev. Biol. Stand. Basel, Karger 84, 195-200 and US patent 5.185.146).

According to the present invention, DNA sequences (genes) which code for dengue antigens is introduced, with the aid of DNA recombination techniques, into the genome of MVA. When the DNA sequence encoding the dengue antigen is integrated at a site in the viral DNA which is non-essential for the life cycle of the virus, e.g. one of the above mentioned deletions, the newly produced recombinant MVA will be infectious, that is to say able to infect foreign cells and it will express the integrated DNA sequence. The recombinant MVA according to the invention will be useful as extremely safe live vaccines for the treatment or prophylaxis of infectious diseases.

Objects of the Invention

It is thus an object of the present invention to provide a recombinant MVA virus expressing dengue virus antigens, which can serve as an efficient and exceptionally safe dengue virus vaccine.

It is a further object of the present invention to provide vaccines for the immunisation of a living animal body, including a human, infected with dengue virus, and for the prevention of dengue virus infection.

Summary of the Invention

The present invention thus, inter alia, comprises the following, alone or in combination:

A recombinant MVA containing and capable of expressing one or more DNA sequences encoding dengue virus antigens;

a recombinant MVA as above containing and capable of expressing DNA sequences encoding antigens from all four dengue virus serotypes (type 1, 2, 3 and 4);

a recombinant-MVA as above wherein the dengue virus antigens is selected from preM, E and/or NS1 antigens;

a recombinant MVA as above wherein the DNA sequences are inserted at the site of naturally occurring deletions within the MVA genome;

a recombinant MVA as above wherein the DNA sequences encoding antigen is under transcriptional control of the vaccinia virus early/late promoter P7.5;

a vaccine containing at least one recombinant MVA as above, and a pharmaceutically acceptable carrier or diluent;

a vaccine as above containing a recombinant MVA encoding a dengue virus type 1 antigen; a recombinant MVA encoding a dengue virus type 2 antigen; a recombinant MVA encoding a dengue virus type 3 antigen, and a recombinant MVA encoding a dengue virus type 4 antigen, and a pharmaceutically acceptable carrier or diluent;

a method for the treatment or prevention of dengue virus infection comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a recombinant MVA as above, or a vaccine as above.

a vaccine comprising as a first component a recombinant MVA carrying and capable of expressing T7RNA polymerase and as further components one or more recombinant DNA vectors each carrying at least one dengue virus antigen under transcriptional control of a T7 RNA polymerase promoter; and

a method for the treatment or prevention of a dengue virus infection comprising inoculating a living animal body, including a human, in need thereof with the first and further components of the vaccine as above either simultaneously or with a timelag but using the same inoculation site.

The present invention

Modified vaccinia virus Ankara (MVA), is a host range restricted and highly attenuated vaccinia virus strain, which is unable to multiply in human and most other mammalian cell lines tested. But since viral gene expression is unimpaired in non-permissive cells

recombinant MVA viruses may be used as exceptionally safe and efficient expression vectors.

The present invention relates to recombinant MVA which contain at least one DNA sequence which codes for a dengue virus antigen and vaccines containing such viruses in a physiologically acceptable form. The invention also relates to methods for the preparation of such recombinant MVA and vaccines, and to the use of these vaccines for the prophylaxis or treatment of infections caused by dengue virus.

The flavivirus genome consists of a single-stranded positive sense RNA molecule. The single encoded open reading frame (ORF) is translated into a polypeptide which is cleaved co- and post-translationally into at least 11 proteins. The order of proteins encoded in the ORF is 5'-C-preM(M)-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3' (Venugopal, K., and Gould, E.A., 1994, Vaccine, Vol. 12, No. 11).

As mentioned above, experiments indicate that structural preM and E proteins, and non-structural NS1 proteins are valuable antigens useful for vaccination purposes.

The preM protein (18-19 kDa) is a precursor of the structural protein M, which is formed by cleavage and removal of the *N*-terminal (pre) segment, by a process presumed to be linked to maturation of the envelope glycoprotein and the development of virus infectivity.

The E glycoprotein (53-54 kDa) is an outer structural protein of the dengue virus. It exhibits a number of biological activities including receptor binding and membrane fusion, and is the target for neutralizing antibodies and T-helper cells. The E protein is a typical membrane glycoprotein with a C-terminal that spans the membrane. The non-structural protein NS1 (39-41 kDa) is also modified by glycosylation. It is derived from the ORF by N-terminal signalase cleavage and C-terminal cleavage involving a protease. NS1 may be involved in the assembly and release of virions. It is found on the cell surface and in the culture medium of infected cells. During the course of infection, NS1 protein evokes a strong antibody response which protects the host against challenge with flaviviruses, presumably through a complement mediated pathway, although recently it has been suggested that other mechanisms such as

antibody-dependent cell cytotoxicity may also be responsible (Venugopal, K., and Gould, E.A., 1994, Vaccine, Vol. 12, No. 11).

Dengue viruses are divided into four antigenically related serotypes, called dengue virus serotypes 1, 2, 3, and 4. The complete or partial nucleotide sequence of the dengue 1, 2, 3, and 4 type virus have been published (Chamber, T.J., Hahn, C.S., Galler, R. And Rice, C.M. 1990. Annu. Rev. Microbiol., 44, 649, Zhao et al., 1986, Virology 155, 77-88).

The recombinant MVA according to the invention contain and are capable of expressing one or more DNA sequences encoding dengue virus antigens.

In one embodiment, the recombinant MVA according to the invention contain and is capable of expressing antigens from both dengue virus type 1, type 2, type 3 and type 4.

In a preferred embodiment of the invention the dengue virus antigen is selected from preM, E and/or NS1 antigens originating from dengue virus type 1, 2, 3 or 4.

The invention also relates to vaccines comprising recombinant MVA according to the invention containing and capable of expressing one or more DNA sequences encoding dengue virus antigens.

In one embodiment, the vaccine according to the invention comprises a recombinant MVA encoding dengue virus type 1 antigen; recombinant MVA encoding dengue virus type 2 antigen; recombinant MVA encoding dengue virus type 3 antigen; and recombinant MVA encoding dengue virus type 4 antigen.

In a further embodiment of the invention recombinant MVA encoding T7 RNA polymerase is used in combination with DNA vectors carrying DNA sequences encoding dengue antigens under transcriptional control of a T7 RNA polymerase promoter.

According to this embodiment, a coding sequence of a given dengue antigen (e.g preM, E, and/or NS1) are cloned under control of a T7 RNA polymerase promoter preferably in a plasmid vector and the resulting DNA construct is amplified and purified using standard laboratory procedures. Secondly, the vector DNA is inoculated simultaneously or with appropriate time lags together with MVA-T7pol. At the site of inoculation the recombinant

gene of interest is expressed transiently in cells containing both the vector DNA and MVA-T7 pol and the corresponding antigen is presented to the host immune system stimulating an antigen-specific immune response. This protocol using the vaccinia vector MVA-T7 pol represents a promising novel approach to nucleic acid vaccination allowing efficient transient expression of a given antigen, but avoiding the potential risk of constitutive gene expression.

The recombinant MVA according to the invention can also carry a marker gene. Said marker genes are preferably selected from the group consisting of marker genes which codes for proteins such as β -galactosidase, neomycin, alcohol dehydrogenase, luciferase, puromycin, hypoxanthine phosphoribosyl transferase (HPRT), hygromycin, secreted alkaline phosphatase and green or blue fluorescent proteins.

The recombinant MVA vaccinia viruses can be prepared as set out hereinafter.

A DNA-construct which contains a DNA-sequence which codes for a dengue antigen flanked by MVA DNA sequences adjacent to a naturally occurring deletion, e.g. deletion II, within the MVA genome, is introduced into cells infected with MVA, to allow homologous recombination.

Once the DNA-construct has been introduced into the eukaryotic cell and the foreign DNA has recombined with the viral DNA, it is possible to isolate the desired recombinant vaccinia virus in a manner known per se, preferably with the aid of a marker (compare Nakano et al., Proc. Natl. Acad. Sci. USA 79, 1593-1596 [1982], Franke et al., Mol. Cell. Biol. 1918-1924 [1985], Chakrabarti et al., Mol. Cell. Biol. 3403-3409 [1985], Fathi et al., Virology 97-105 [1986]).

The DNA-construct to be inserted can be linear or circular. A circular DNA is preferred, especially a plasmid. The DNA-construct contains sequences flanking the left and the right side of a naturally occurring deletion, e.g. deletion II, within the MVA genome (Altenburger, W., Suter, C.P. and Altenburger J. (1989) Arch. Virol. 105, 15-27). The DNA sequence encoding dengue virus antigen is inserted between the sequences flanking the naturally occurring deletion.

For the expression of a DNA sequence encoding a dengue virus antigen, it is necessary for regulatory sequences, which are required for the transcription of the DNA sequence,

to be present on the DNA. Such regulatory sequences (called promoters) are known to those skilled in the art, and includes for example those of the vaccinia 11 kDa gene as are described in EP-A-198, 328, and those of the 7.5 kDa gene (EP-A-110, 385).

The DNA-construct can be introduced into the MVA infected cells by transfection, for example by means of calcium phosphate precipitation (Graham et al., *Viol.* 52, 456-467 [1973]; Wigler et al., *Cell* 777-785 [1979] by means of electroporation (Neumann et al., *EMBO J.* 1, 841-845 [1982]), by microinjection (Graessmann et al., *Meth. Enzymology* 101, 482-492 (1983)), by means of liposomes (Straubinger et al., *Methods in Enzymology* 101, 512-527 (1983)), by means of spheroplasts (Schaffner, *Proc. Natl. Acad. Sci. USA* 77, 2163-2167 (1980)) or by other methods known to those skilled in the art. Transfection by means of calcium phosphate precipitation is preferred.

For the preparation of vaccines, the recombinant MVA according to the invention are converted into a physiologically acceptable form. This can be done based on the experience in the preparation of MVA vaccines used for vaccination against smallpox (as described by Stickl, H. et al. [1974] *Dtsch. med. Wschr.* 99, 2386-2392). Typically, about 10^6 - 10^8 particles of the recombinant MVA are freeze-dried in 100ml of phosphate-buffered saline (PBS) in the presence of 2% peptone and 1% human albumin in an ampoule, preferably a glass ampoule. The lyophilisate can contain extenders (such as mannitol, dextran, sugar, glycine, lactose or polyvinylpyrrolidone) or other aids (such as antioxidants, stabilizers, etc.) suitable for parenteral administration. The glass ampoule is then sealed and can be stored, preferably at temperatures below -20°C ., for several months.

For vaccination or therapy the lyophilisate can be dissolved in 0.1 to 0.5 ml of an aqueous solution, preferably physiological saline, and administered either parenterally, for example by intramuscular inoculation or locally. Vaccines or therapeutics according to the invention are preferably injected intramuscularly (Mayr, A. et al. [1978] *Zbl. Bakt. Hyg., I. Abt. Orig. B* 167, 375-390). The mode of administration, the dose and the number of administrations can be optimized by those skilled in the art in a known manner. It is expedient where appropriate to administer the vaccine several times over a lengthy period in order to obtain appropriate immune responses against the foreign antigen.

The detailed examples which follow are intended to contribute to a better understanding of the present invention. However, it is not intended to give the impression that the invention is confined to the subject-matter of the examples.

The drawings

- Figure 1: Schematic map of the genome of MVA and plasmid for insertion of foreign DNA by homologous recombination: *Hind*III restriction sites within the genome of MVA are indicated at the top. The 900-bp *Hind*III-*Hind*III N fragment that overlaps the junction of deletion II within the MVA genome is shown. MVA DNA sequences adjacent to deletion II (flank1 and flank2) were amplified by PCR and used for the construction of insertion plasmid pUC II LZ.
- Figure 2: pUC II LZ P7.5: MVA vector plasmid for insertion into deletion II containing P11-LacZ expression cassette and the vaccinia virus early/late promoter P7.5 to express genes of interest that can be cloned into the *Sma*I site of the plasmid.
- Figure 3: pUCII LZdel P7.5: MVA vector plasmid for insertion of foreign genes at the site of deletion II in the MVA genome, containing a self-deleting P11-LacZ expression cassette and the vaccinia virus early/late promoter P7.5 to express genes of interest that can be cloned into the *Sma*I / *Not*I cloning site of the plasmid.
- Figure 4: Construction of recombinant virus MVA-T7pol: schematic maps of the MVA genome (*Hind*III restriction endonuclease sites) and the vector plasmid pUC II LZ T7pol that allows insertion of the T7 RNA polymerase gene at the site of deletion II within the *Hind*III N fragment of the MVA genome.
- Figure 5: Southern blot analysis of MVA-T7pol viral DNA
- Figure 6: Metabolic labeling of proteins using [³⁵S]methionine. SDS PAGE analysis. Lane 1: MVA T7pol, Lane 2: MVA, lane 3: CV-1 cells.
- Figure 7: CAT assay: CV-1 cells transfected with plasmid containing CAT gene under control of T7 RNA polymerase promoter and infected with MVA-T7pol or WR-T7pol. Lysates were tested for CAT activity. C means

chloramphenicol, and 1-AcC and 3-AcC means mono and tri acetylated forms of chloramphenicol. Cat activity is expressed as percentage of acetylated product formed in 60 min.

Example 1

Growing of the MVA virus

The MVA virus is a highly attenuated vaccinia virus derived from the vaccinia virus strain Ankara (CVA) by long-term serial passages on primary chicken embryo fibroblast (CEF) cultures. For a general review of the history of the production, the properties and the use of MVA strain, reference may be made to the summary published by Mayr et al. in *Infection* 3, 6-14 [1975]. Due to the attenuation in CEF, the MVA virus replicates to high titers in this avian host cell. In mammalian cells, however, MVA is severely growth restricted, and typical plaque formation by the virus is not detectable. Therefore, MVA virus was grown on CEF cells. To prepare CEF cells, 11-days old embryos were isolated from incubated chicken eggs, the extremities are removed, and the embryos are minced and dissociated in a solution composed of 0.25% trypsin at 37 °C for 20 minutes. The resulting cell suspension was filtered and cells were sedimented by centrifugation at 2000 rpm in a Sorvall RC-3B centrifuge at room temperature for 5 minutes, resuspended in 10 volumes of medium A (MEM Eagle, for example obtainable from Life Technologies GmbH, Eggenstein, Germany), and sedimented again by centrifugation at 2000 rpm in a Sorvall RC-3B centrifuge at room temperature for 5 minutes. The cell pellet was reconstituted in medium A containing 10% fetal calf serum (FCS), penicillin (100 units/ml), streptomycin (100 mg/ml) and 2 mM glutamine to obtain a cell suspension containing 500 000 cells/ml. CEF cells obtained in this way were spread on cell culture dishes. They were left to grow in medium A in a CO₂ incubator at 37°C for 1-2 days, depending on the desired cell density, and were used for infection either directly or after one further cell passage. A detailed description of the preparation of primary cultures can be found in the book by R.I. Freshney, "Culture of animal cell", Alan R. Liss Verlag, New York [1983] Chapter 11, page 99 et seq.

MVA viruses were used for infection as follows. CEF cells were cultured in 175 cm² cell culture bottles. At 90-100% confluence, the medium was removed and the cells were incubated for one hour with an MVA virus suspension (0.01 infectious units (IU) per cell, 0.02 ml/cm²) in medium A. Then more medium A was added (0.2 ml/cm²) and the bottles were incubated at 37°C for 2-3 days (until about 90% of the cells show cytopathogenic effect). Crude virus stocks were prepared by scraping cell monolayers into the medium and pelleting the cell material by centrifugation at 3000 rpm in a

Sorvall RC-3B centrifuge at 4 °C for 5 minutes. The crude virus preparation was stored at -20°C before further processing (e.g. virus purification).

Example 2

Cloning of MVA virus

To generate homogeneous stock virus preparations MVA virus obtained from Prof. Anton Mayr was cloned by limiting dilution during three consecutive passages in CEF cultured on 96-well tissue culture plates. The MVA clone F6 was selected and amplified in CEF to obtain working stocks of virus that served as starting material for the generation of recombinant MVA viruses described in this patent application as well as for the generation of recombinant MVA viruses described previously (Sutter, G. and Moss, B. [1992] *Proc. Natl. Acad. Sci. USA* 89, 10847-10851; Sutter, G., Wyatt, L., Foley, P., Bennink, J. and Moss, B. [1994] *Vaccine* 12, 1032-1040; Hirsch, V., Fuerst, T., Sutter, G., Carroll, M., Yang, L., Goldstein, S., Piatak, M., Elkins, W., Alvord, G., Montefiori, D., Moss, B. and Lifson, J. [1996] *J. Virol.* 70, 3741-3752).

Example 3

Purification of the viruses

The purification steps undertaken to obtain a virus preparation which was as pure as possible and free from components specific to the host cell were similar to those described by (Joklik, *Virology* 18, 9-18 [1962]). Crude virus stocks which had been stored at -20°C. were thawed and suspended once in PBS (10-20 times the volume of the sediment), and the suspension was centrifuged as above. The new sediment was suspended in 10 times the volume of Tris buffer 1 (10mM Tris-HCl pH 9.0.), and the suspension was briefly treated with ultrasound (Labsonic L, B.Braun Biotech International, Melsungen Germany; 2x10 seconds at 60 watts and room temperature) in order to further disintegrate cell debris and to liberate the virus particles from the cellular material. The cell nuclei and the larger cell debris were removed in the subsequent brief centrifugation of the suspension (Sorvall GSA rotor obtainable from DuPont Co., D-6353 Bad Nauheim, FRG; 3 minutes at 3000 rpm and 10° C.). The sediment was once again suspended in Tris buffer 1, treated with ultrasound and centrifuged, as described above. The collected supernatants containing the free virus particles were combined and layered over a cushion of 10 ml of 36% sucrose in 10 mM

Tris-HCl, pH 9.0, and centrifuged in a Beckman SW 27/SW 28 rotor for 80 minutes with 13,500 rpm at 4° C. The supernatant was discarded, and the sediment containing the virus particles was taken up in 10 ml of 1 mM Tris-HCl, pH 9.0, homogenized by brief treatment with ultrasound (2x10 seconds at room temperature, apparatus as described above), and applied to a 20-40% sucrose gradient (sucrose in 1 mM Tris-HCl, pH 9.0) for further purification. The gradient was centrifuged in Beckmann SW41 rotor at 13,000 rpm for 50 minutes at 4° C. After centrifugation, discrete bands containing virus particles were harvested by pipetting after aspirating volume above band. The obtained sucrose solution was diluted with three volumes PBS and the virus particles were sedimented again by centrifugation (Beckmann SW 27/28, 60 minutes at 13,500 rpm, 4° C.). The pellet, which now consisted mostly of pure virus particles, was resuspended in PBS and equilibrated to virus concentrations corresponding on average to $1-5 \times 10^9$ IU/ml. The purified virus stock solution was stored at -80 °C and used either directly or diluted with PBS for subsequent experiments.

Example 4

Construction and characterization of recombinant MVA viruses

Construction of vector plasmids: To allow the generation of recombinant MVA viruses novel vector plasmids were constructed. Insertion of foreign genes into the MVA genome was targeted precisely to the site of the naturally occurring deletion II in the MVA genome. Sequences of MVA DNA flanking the site of a 2500-bp deletion in the *HindIII* N fragment of the MVA genome (Altenburger, W., Suter, C.P. and Altenburger, J. [1989], J. Arch. Virol. 105, 15-27) were amplified by PCR and cloned into the multiple cloning site of plasmid pUC18. The primers for the left 600-bp DNA flank were 5'-CAG CAG GGT ACC CTC ATC GTA CAG GAC GTT CTC-3' and 5'-CAG CAG CCC GGG TAT TCG ATG ATT ATT TTT AAC AAA ATA ACA-3' (sites for restriction enzymes *KpnI* and *SmaI* are underlined). The primers for the right 550-bp DNA flank were 5'-CAG CAG CTG CAG GAA TCA TCC ATT CCA CTG AAT AGC-3' and 5'-CAG CAG GCA TGC CGA CGA ACA AGG AAC TGT AGC AGA-3' (sites for restriction enzymes *PstI* and *SphI* are underlined). Between these flanks of MVA DNA inserted in pUC18, the *Escherichia coli lacZ* gene under control of the vaccinia virus late promoter P11 (prepared by restriction digest from pIII LZ, Sutter, G. and Moss, B. [1992] PNAS USA 89, 10847-10851) was inserted, using the *BamHI* site, to generate the MVA insertion vector pUCII LZ

[Figure 1]. In the following, a 289 bp fragment containing the vaccinia virus early-late promoter P7.5 together with a *Sma*I site for cloning (prepared by restriction digest with *Eco*RI and *Xba*I from the plasmid vector pSC11 [Chakrabarti et al. 1985, Molecular and Cellular Biology 5, 3403-3409]) was inserted into the *Sma*I site of pUCII LZ to give the MVA vector pUC II LZ P7.5 [Figure 2]. To construct a vector plasmid that allows isolation of recombinant MVA viruses via transient synthesis of the reporter enzyme β -galactosidase a 330 bp DNA fragment from the 3'-end of the *E. coli* *LacZ* open reading frame was amplified by PCR (primers were 5'-CAG CAG GTC GAC CCC GAC CGC CTT ACT GCC GCC-3' and 5'-GGG GGG CTG CAG ATG GTA GCG ACC GGC GCT CAG-3') and cloned into the *Sa*I and *Pst*I sites of pUC II LZ P7.5 to obtain the MVA vector pUC II LZdel P7.5 [Figure 3]. Using the *Sma*I site, this vector plasmid can be used to insert DNA sequences encoding a foreign gene under transcriptional control of the vaccinia virus promoter P7.5 into the MVA genome. After the desired recombinant virus has been isolated by screening for expression of β -galactosidase activity further propagation of the recombinant virus leads to the self-deletion of the reengineered P11-*LacZ* expression cassette by homologous recombination.

Example 5

Construction of recombinant MVA-preM-E encoding structural preM and E glycoprotein of dengue virus.

A cDNA fragment encoding amino acids 100-773 of dengue virus type 4 comprising a signal sequence of 14 amino acids preceding preM and all amino acids of preM and E including 40 amino acid residues at the C-terminus of E was isolated by PCR from dengue virus type 4 cDNA (Zhao et al., 1986, Virology 155, 77-88).

The fragment was cloned into the *Sma*I site of pUCIILZdelP7.5 to create pUCIILZdelP7.5-preM-E carrying the preM-E fragment under transcriptional control of the vaccinia virus early/late promoter P7.5.

The fragment carrying the preM-E fragment under transcriptional control of the vaccinia virus early/late promoter P7.5 was inserted into deletion II within the MVA using homologous recombination: CEF cells infected with MVA at a multiplicity of 0.05 TCID₅₀ per cell were transfected with DNA of plasmid pUC II LZdel P7.5-preM-E as described

previously (Sutter, G, Wyatt, L., Foley, P., Bennink, J. and Moss, B. [1994] Vaccine 12, 1032-1040). Recombinant MVA viruses containing the preM-E sequence and transiently co-expressing the *E. coli LacZ* marker gene were selected by consecutive rounds of plaque purification in CEF cells stained with 5-bromo-4-chloro-3-indolyl β -D-galactoside (300 μ g/ml). In the following, recombinant MVA viruses containing the preM-E sequence and having deleted the *LacZ* marker gene were isolated by three additional consecutive rounds of plaque purification screening for non-staining viral foci in CEF cells in the presence of 5-bromo-4-chloro-3-indolyl β -D-galactoside (300 μ g/ml). Subsequently, recombinant viruses were amplified by infection of CEF monolayers.

Example 6

Construction of recombinant MVA-NS1 encoding non-structural NS1 glycoprotein of Dengue virus.

A cDNA fragment encoding amino acids 750 to 1125 of dengue virus serotype 4 comprising a signalsequence of 24 amino acids preseding NS1 and all NS1 residues until alanine 1125 was isolated by PCR from Dengue virus type 4 cDNA (Zhao et al., 1986, Virology 155, 77-88).

The fragment was cloned into the *Sma*I site of pUC11LZdelP7.5 to create pUC11LZdelP7.5-NS1 carrying the NS1 fragment under transcriptional control of the vaccinia virus early/late promoter P7.5.

The fragment carrying the NS1 fragment under transcriptional control of the vaccinia virus early/late promoter P7.5 was inserted into deletion II within the MVA using homologous recombination as describe in example 5.

Example 7

Construction and characterization of recombinant virus MVA T7pol

A 3.1 kbp DNA fragment containing the entire gene of bacteriophage T7 RNA polymerase under control of the vaccinia virus early/late promoter P7.5 was excised with *Eco*RI from plasmid pTF7-3 (Fuerst, T.R., Niles, E.G., Studier, F.W. and Moss, B., 1986,

P. N. A. S. USA 83, 8122-8126), modified by incubation with Klenow DNA polymerase to generate blunt ends, and cloned into a unique *Sma*I restriction site of pUCII LZ to make the plasmid transfer vector pUCII LZ T7pol [Figure 4]. As transcriptional regulator for the expression of the T7 RNA polymerase gene the vaccinia virus early/late promoter P7.5 was chosen. Contrary to stronger vaccinia virus late promoters (e.g. P11) this promoter system allows expression of recombinant genes immediately after the infection of target cells. The plasmid pUCII LZ T7pol that directs the insertion of the foreign genes into the site of deletion II of the MVA genome was used to generate the recombinant virus MVA T7pol.

CEF cells infected with MVA at a multiplicity of 0.05 TCID₅₀ per cell were transfected with DNA of plasmid pUCII LZ T7pol as described previously (Sutter, G, Wyatt, L., Foley, P., Bennink, J. and Moss, B. (1994) Vaccine 12, 1032-1040). Recombinant MVA virus expressing the T7 RNA polymerase and co-expressing β -D-galactosidase (MVA P7.5-T7pol) was selected by five consecutive rounds of plaque purification in CEF cells stained with 5-bromo-4-chloro-3-indolyl β -D-galactoside (300 μ g/ml).

Subsequently, recombinant viruses were amplified by infection of CEF monolayers, and the DNA was

analyzed by PCR to confirm genetic homogeneity of the virus stock. Southern blot analysis of MVA-T7pol viral DNA demonstrated stable integration of the recombinant genes at the site of deletion II within the MVA genome [Figure 5].

To monitor expression of T7 RNA polymerase by recombinant MVA T7pol

[³⁵S]methionine -labeled polypeptides from virus infected tissue culture were analyzed.

Monolayers of the monkey kidney cell line CV-1 grown in 12-well plates were infected with virus at a multiplicity of 20 TCID₅₀ per cell. At 3 to 5 hours after infection, the medium was removed, and the cultures were washed once with 1 ml of methionine free medium.

To each well, 0.2 ml of methionine-free medium supplemented with 50 μ Ci of

[³⁵S]methionine was added and incubated for 30 min at 37°C. Cytoplasmic extracts of infected cells were prepared by incubating each well in 0.2 ml of 0.5% Nonidet P-40 lysis buffer for 10 min at 37°C and samples were analyzed by SDS-PAGE. The metabolic labeling of the CV-1 cells with MVA T7pol revealed the synthesis of two additional polypeptides (i) a protein of about 116,000 Da representing the E. coli β -galactosidase co-expressed to allow the screening for recombinant virus and (ii) a 98,000 Da protein with the expected size of the bacteriophage T7 RNA polymerase [Figure 6]. The large amount of β -galactosidase made by MVA T7pol is remarkable. The results from the *in vivo* labeling experiments demonstrate a very strong expression of the P11-*LacZ* gene

construct when inserted into the MVA genome at the site of deletion II indicating that recombinant genes in MVA vector viruses might be expressed more efficiently when inserted into this locus of the MVA genome.

The usefulness of MVA-T7pol recombinant viruses as expression system in comparison to the WR-T7pol recombinant virus vTF7-3 (Fuerst et al. 1986) was tested by the co-transfection of DNA of a plasmid vector that is derived from pTM1 (Moss, B., Elroy-Stein, O., Mizukami, T., Alexander, W.A., and Fuerst T.R. (1990) *Nature* 348, 91-92) and contains (cloned into the *NcoI* and *BamHI* sites of the pTM1 multiple cloning site) the *E. coli* chloramphenicol acetyltransferase (CAT) gene under the control of a T7 RNA polymerase promoter (PT₇). Transfected and infected CV-1 cells were suspended in 0.2 ml of 0.25 M Tris-HCl (pH 7.5). After three freeze-thaw cycles, the lysates were cleared by centrifugation, the protein content of the supernatants was determined, and samples containing 0.5, 0.25, 0.1 µg total protein were assayed for enzyme activity as described by Mackett, M., Smith, G.L. and Moss, B. (1984) *J. Virol.* 49, 857-864. After autoradiography, labeled spots were quantitated using the Fuji imaging analysis system. The results demonstrate that by using the highly attenuated vaccinia vector MVA it is possible to exploit the vaccinia virus-T7 RNA polymerase system as efficiently as by using a fully replication-competent vaccinia virus recombinant [Figure 7].

Recombinant DNA vectors encoding dengue virus antigens under transcriptional control of the T7 RNA polymerase promoter can be used in combination with the MVA-T7pol for vaccination purposes.

Claims:

1. A recombinant MVA containing and capable of expressing one or more DNA sequences encoding dengue virus antigens.
2. A recombinant MVA according to claim 1 containing and capable of expressing DNA sequences encoding antigens from all four dengue virus serotypes (type 1, 2, 3 and 4).
3. A recombinant MVA according to claims 1 to 2 wherein the dengue virus antigen is selected from preM, E and/or NS1 antigens.
4. A recombinant MVA according to claims 1 to 3 wherein the DNA sequences are inserted at the site of naturally occurring deletions within the MVA genome.
5. A recombinant MVA according to claims 1 to 4 wherein the DNA sequences encoding antigen is under transcriptional control of the vaccinia virus early/late promoter P7.5.
6. A vaccine containing at least one recombinant MVA according to claims 1 to 5 and a pharmaceutically acceptable carrier or diluent.
7. A vaccine according to claim 6 containing a recombinant MVA encoding a dengue virus type 1 antigen; a recombinant MVA encoding a dengue virus type 2 antigen; a recombinant MVA encoding a dengue virus type 3 antigen, and a recombinant MVA encoding a dengue virus type 4 antigen, and a pharmaceutically acceptable carrier or diluent.
8. A method for the treatment or prevention of dengue virus infection comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a recombinant MVA according to claims 1 to 5, or a vaccine according to claims 6 to 7.
9. A vaccine comprising as a first component a recombinant MVA carrying and capable of expressing T7RNA polymerase and as further components one or more

recombinant DNA vectors each carrying at least one dengue virus antigen under transcriptional control of a T7 RNA polymerase promoter.

10. A method for the treatment or prevention of a dengue virus infection comprising inoculating a living animal body, including a human, in need thereof with the first and further components of a vaccine according to claim 9 either simultaneously or with a timelag but using the same inoculation site.

Abstract

Recombinant MVA viruses containing and capable of expressing dengue virus antigens and the use of such recombinant MVA for vaccination.

MVA *Hind*III





FIG. 1

clone #9



clone #14




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7